2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2945

Diffuse Alveolar Hemorrhage in SLE: Risk Factors, Response to Therapy, and Survival
Abstract Number: 2946

Mortality Among SLE Patients in the National Data Bank for Rheumatic Diseases
Abstract Number: 2947

Association of Anti-NR2 and U1RNP Antibodies with Neurotoxic Inflammatory Mediators in Cerebrospinal Fluid from Patients with Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 2948

How Do Patients with Newly Diagnosed SLE Present? a Multicenter Cohort Analysis to Inform the Development of New Classification Criteria for SLE
Abstract Number: 2949

Differential Serum Cytokine Profile in Patients with Systemic Lupus Erythematosus and Posterior Reversible Encephalopathy Syndrome: A Single-Center Study
Abstract Number: 2950

Using Electronic Health Record Algorithms to Accurately Identify Patients with Systemic Lupus Erythematosus
Abstract Number: 2951

Anti-NR2 Antibody and Blood-Brain Barrier Disruption in Systemic Lupus Erythematosus Patients with Cognitive Dysfunction
Abstract Number: 2952

Diagnosis of Primary Neuropsychiatric Systemic Lupus Erythematosus: Attribution Models Versus Physician Judgment
Abstract Number: 2953

The Emergency Room and SLE: What Characteristics Are Associated with Increased Emergency Room Utilization in Lupus Patients?
Abstract Number: 2954

Serum and CSF Biomarkers of Neuropsychiatric Involvement in Primary Sjogren Syndrome and Systemic Lupus Erythematosus
Abstract Number: 2955

Cognitive Impairment in Lupus Patients: Identification of the Best Screening Test and Assessment for Associated Factors
Abstract Number: 2956

Patients’ Reported Perceived Deficits Questionnaire – 5-Item Is Not Valid to Screen for Cognitive Impairment in Lupus
Abstract Number: 2957

25-Hydroxyvitamin D3 Deficiency Independently Predicts Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Results from a Controlled Study
Abstract Number: 2958

Vitamin D, Cognition and Cerebral Structural Abnormalities in Childhood- Onset Systemic Lupus Erythematosus
Abstract Number: 2959

Patterns of Vascular Brain Injury in Systemic Lupus Erythematosus Patients with Ischemic Stroke: Impact on Neuropsychological, Neurobehavioral and Physical Function Outcome

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].